UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 133

Sortiert nach

The promise and challenges of immune agonist antibody development in cancer

Nature reviews. Drug discovery, 2018-07, Vol.17 (7), p.509-527

2018

Link zum Volltext

Verfügbarkeit prüfen

Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations

Nature reviews. Drug discovery, 2016-04, Vol.15 (4), p.235-247

Hoos, Axel

2016

Link zum Volltext

Verfügbarkeit prüfen

Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy

Blood, 2016-11, Vol.128 (21), p.2489-2496

2016

Link zum Volltext

Verfügbarkeit prüfen

Industrializing engineered autologous T cells as medicines for solid tumours

Nature reviews. Drug discovery, 2021-06, Vol.20 (6), p.476-488

2021

Link zum Volltext

Verfügbarkeit prüfen

Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

Blood cancer journal (New York), 2019-03, Vol.9 (4), p.37-37, Article 37

2019

Link zum Volltext

Verfügbarkeit prüfen

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

The New England journal of medicine, 2011-06, Vol.364 (26), p.2517-2526

2011

Link zum Volltext

Verfügbarkeit prüfen

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy

Journal of clinical oncology, 2018-03, Vol.36 (9), p.850-858

2018

Link zum Volltext

Verfügbarkeit prüfen

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Clinical cancer research, 2009-12, Vol.15 (23), p.7412-7420

2009

Link zum Volltext

Verfügbarkeit prüfen

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

Annals of the New York Academy of Sciences, 2013-07, Vol.1291 (1), p.1-13

2013

Link zum Volltext

Verfügbarkeit prüfen

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

The lancet oncology, 2010-02, Vol.11 (2), p.155-164

2010

Link zum Volltext

Verfügbarkeit prüfen

Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy

Seminars in oncology, 2010-10, Vol.37 (5), p.533-546

2010

Link zum Volltext

Verfügbarkeit prüfen

Guidelines for the automated evaluation of Elispot assays

Nature protocols, 2015-07, Vol.10 (7), p.1098-1115

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group

Journal of clinical oncology, 2008-02, Vol.26 (6), p.955-962

2008

Link zum Volltext

Verfügbarkeit prüfen

A methodological framework to enhance the clinical success of cancer immunotherapy

Nature biotechnology, 2011-10, Vol.29 (10), p.867-870

2011

Link zum Volltext

Verfügbarkeit prüfen

Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study

Blood cancer journal (New York), 2020-10, Vol.10 (10), p.106, Article 106

2020

Link zum Volltext

Verfügbarkeit prüfen

Tissue Microarray Profiling of Cancer Specimens and Cell Lines: Opportunities and Limitations

Laboratory investigation, 2001-10, Vol.81 (10), p.1331-1338

2001

Link zum Volltext

Verfügbarkeit prüfen

The regulatory landscape for actively personalized cancer immunotherapies

Nature biotechnology, 2013-10, Vol.31 (10), p.880-882

2013

Link zum Volltext

Verfügbarkeit prüfen

Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas

Annals of surgery, 2002-03, Vol.235 (3), p.424-434

2002

Link zum Volltext

Verfügbarkeit prüfen

Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)

Cancer Immunology, Immunotherapy, 2008-03, Vol.57 (3), p.303-315

2008

Link zum Volltext

Verfügbarkeit prüfen

Adaptation and modification of the immune related response criteria (IRRC): IrRECIST

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e22121-e22121

2014

Link zum Volltext

Verfügbarkeit prüfen

The immuno-oncology framework: Enabling a new era of cancer therapy

Oncoimmunology, 2012-05, Vol.1 (3), p.334-339

2012

Link zum Volltext

Verfügbarkeit prüfen

The European Regulatory Environment of RNA-Based Vaccines

Methods in molecular biology (Clifton, N.J.), 2017-01, Vol.1499, p.203

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 133

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(125)
Mit Volltextzugriff
(118)

Publikationsform

Sprache

Englisch
(132)
Japanisch
(23)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(80)
Humans
(78)
Life Sciences & Biomedicine
(77)
Oncology
(49)
Female
(41)
Biological And Medical Sciences
(39)
Medical Sciences
(39)
Middle Aged
(37)
Male
(35)
Aged
(28)
Adult
(25)
Tumors
(24)
Immunotherapy
(20)
Cancer
(19)
Ipilimumab
(17)
Antibodies, Monoclonal - Therapeutic Use
(16)
Treatment Outcome
(16)
Aged, 80 And Over
(15)
Immunology
(15)
Prognosis
(15)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The promise and challenges of immune agonist antibody development in cancer

Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations

Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy

Industrializing engineered autologous T cells as medicines for solid tumours

Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy

Guidelines for the automated evaluation of Elispot assays

Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group

A methodological framework to enhance the clinical success of cancer immunotherapy

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study

Tissue Microarray Profiling of Cancer Specimens and Cell Lines: Opportunities and Limitations

The regulatory landscape for actively personalized cancer immunotherapies

Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas

Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)

Adaptation and modification of the immune related response criteria (IRRC): IrRECIST

The immuno-oncology framework: Enabling a new era of cancer therapy

The European Regulatory Environment of RNA-Based Vaccines

Suchergebnisse filtern